Nanoparticle-mediated drug delivery system for coronary artery disease

Tetsuya Matoba, Jun Ichiro Koga, Kaku Nakano, Kensuke Egashira

Research output: Contribution to journalReview article

Abstract

Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.

Original languageEnglish
Pages (from-to)299-308
Number of pages10
JournalDrug Delivery System
Volume30
Issue number4
DOIs
Publication statusPublished - Dec 25 2015

Fingerprint

Drug Delivery Systems
Nanoparticles
Coronary Artery Disease
Myocardial Infarction
Medicine
Myocardial Reperfusion Injury
Atherosclerotic Plaques
Secondary Prevention
Reperfusion Injury
Reperfusion
Myocardial Ischemia
Rupture
Heart Failure
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Nanoparticle-mediated drug delivery system for coronary artery disease. / Matoba, Tetsuya; Koga, Jun Ichiro; Nakano, Kaku; Egashira, Kensuke.

In: Drug Delivery System, Vol. 30, No. 4, 25.12.2015, p. 299-308.

Research output: Contribution to journalReview article

@article{2a05b6d239a547e7aa982011a9697ded,
title = "Nanoparticle-mediated drug delivery system for coronary artery disease",
abstract = "Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.",
author = "Tetsuya Matoba and Koga, {Jun Ichiro} and Kaku Nakano and Kensuke Egashira",
year = "2015",
month = "12",
day = "25",
doi = "10.2745/dds.30.299",
language = "English",
volume = "30",
pages = "299--308",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "4",

}

TY - JOUR

T1 - Nanoparticle-mediated drug delivery system for coronary artery disease

AU - Matoba, Tetsuya

AU - Koga, Jun Ichiro

AU - Nakano, Kaku

AU - Egashira, Kensuke

PY - 2015/12/25

Y1 - 2015/12/25

N2 - Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.

AB - Coronary artery disease including acute myocardial infarction is a significant concern in cardiovascular medicine, because of their high acute mortality and morbidity causing lethal heart failure. Atherosclerotic plaque destabilization and rupture are central pathogenesis of acute myocardial infarction, whereas myocardial ischemia-reperfusion injury is another adverse phenomenon in the heart undergoing early reperfusion therapy for acute myocardial infarction. There are un-met needs for these pathological conditions to be overcome by the use of nanoparticle-mediated drug delivery system (DDS). We provide overview of the mechanistic background for the use of DDS and the efficacy of nano-medicine in preclinical disease models.

UR - http://www.scopus.com/inward/record.url?scp=84951789812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951789812&partnerID=8YFLogxK

U2 - 10.2745/dds.30.299

DO - 10.2745/dds.30.299

M3 - Review article

AN - SCOPUS:84951789812

VL - 30

SP - 299

EP - 308

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 4

ER -